Why the study?
Does verapamil reduce cardiac hypertrophy markers in patients with hypertrophic obstructive cardiomyopathy?
Population
22 patients with hypertrophic obstructive cardiomyopathy
Design
Case_series
Follow-up
average of 15 months (4 to 24 months)
Authors
Loading...
Hypothesis-generating for verapamil in HOCM; does not support practice change without RCTs.
Does verapamil reduce cardiac hypertrophy markers in patients with hypertrophic obstructive cardiomyopathy?
Verapamil treatment significantly reduced QRS amplitude and heart volume in patients with hypertrophic obstructive cardiomyopathy, suggesting a reduction in left ventricular muscle mass.
Kaltenbach et al. (1979) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: